Mirvetuximab soravtansine for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer
Technology appraisal guidance
Reference number: TA1169
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.